Kisspeptin-10
Also known as: KP-10, Metastin 45-54
Kisspeptin-10 is a fragment of the kisspeptin protein that plays a central role in regulating reproductive hormone signalling. It is a research peptide and is not approved for human use in Australia.
- Category
- Reproductive / Hormonal
- Reported half-life
- Reported to be very short (minutes); not well established
- Common forms
- Investigational injectable (research setting), Lyophilised powder described in research
- Research status
- Research peptide used in reproductive neuroendocrinology studies. Not approved for human use in Australia.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in research to stimulate release of gonadotropin-releasing hormone
- Studied for effects on luteinising hormone and reproductive signalling
- Investigated in fertility and reproductive neuroendocrinology research
How it is reported to work
Kisspeptin-10 is described as the shortest active fragment of kisspeptin that binds the KISS1R (GPR54) receptor on hypothalamic neurons, prompting release of gonadotropin-releasing hormone and downstream pituitary hormones. This positions it upstream of the reproductive hormone axis. These descriptions come from reproductive research and are not those of an approved therapy.
Background
Kisspeptin-10 is a short active fragment of the kisspeptin protein, which sits at the top of the reproductive hormone axis. It is widely used as a research tool in neuroendocrinology. This page is educational information, not medical advice, and does not recommend use.
What the research shows
Reproductive research reports that kisspeptin-10 can stimulate gonadotropin-releasing hormone and downstream hormones. These are reported research findings, not outcomes of an approved product, and broader claims are not established.
| Feature | Reported status |
|---|---|
| Receptor | KISS1R (GPR54) |
| Position in hormone axis | Upstream of GnRH |
| Australian approval | None |
What people use it for (reported)
Online, kisspeptin-10 is reported to attract interest for fertility and hormonal topics, reflecting its position at the top of the reproductive hormone axis. These are anecdotal reports, not validated outcomes, and should not be read as established facts. Effects seen in controlled neuroendocrine studies do not establish that self-directed use is safe or effective.
Things to be aware of
Kisspeptin-10 is a research peptide not approved for human use in Australia, and its long-term safety is not established. Reproductive hormone manipulation can have systemic effects, and grey-market purity cannot be verified.
If you have a fertility or hormonal concern, the appropriate step is to consult a qualified healthcare professional. This article does not endorse obtaining or using kisspeptin-10.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in research to stimulate release of gonadotropin-releasing hormone
- Studied for effects on luteinising hormone and reproductive signalling
- Investigated in fertility and reproductive neuroendocrinology research
- Reported to produce an acute hormonal response after dosing
Common side effects
- Reported injection-site reactions
- Reported flushing
- Reported headache
- Reported transient changes in mood or libido
Rare / serious side effects
- Reported allergic or hypersensitivity-type reactions
- Reported pronounced or unintended shifts in reproductive hormones
- Reported unpredictable effects from unverified grey-market product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Kisspeptin-10. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported self-dosing to manipulate reproductive hormones without medical oversight
- Reported use for unproven fertility or performance goals outside research settings
- Reported dose escalation beyond any researched range seeking stronger hormonal effects
- Reported use of unverified self-sourced product of unknown purity and identity
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Reported as producing an acute reproductive-hormone response within hours of dosing rather than a cumulative effect.
First effects
reported acute hormonal response within hours of a dose
Noticeable change
reported subjective changes over a few weeks of study dosing
Clear results
reported over an extended period; not clinically established for general use
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Kisspeptin-10. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Reported as subcutaneous or intravenous administration in research settings (research only) |
|---|---|
| Typical reported dose | Reported in studies as a bolus of about 0.3-1 mcg/kg, or fixed microgram doses; research-only dosing |
| Frequency | Reported as single boluses or short infusions within study protocols; no established schedule |
| Cycle length | No established cycle length; used within research protocols only |
Reported reconstitution (mg → units)
For injected research use, reported example: a 5 mg vial plus 5 mL bacteriostatic water gives 1 mg/mL. A reported 50 mcg (0.05 mg) dose is about 0.05 mL, which is roughly 5 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorCommonly reported in research as single or intermittent injections to probe hormonal response; this is reported information, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported alongside it for interest in the reproductive hormone axis
Reported in the same reproductive-hormone research context
Reported alongside it anecdotally for interest in sexual and reproductive pathways
Safety notes
Kisspeptin-10 is a research peptide and is not approved for human use in Australia, so its full safety profile is not established. Manipulating reproductive hormone pathways can have systemic effects. Anyone with a fertility or hormonal concern should consult a qualified healthcare professional.